Graft loss following liver transplantation in patients with chronic hepatitis C

Hugo R. Rosen, Patrick M. O'Reilly, Christopher R. Shackleton, Sue Mcdiarmid, Curtis Holt, Ronald W. Busuttil, Paul Martin

Research output: Contribution to journalArticle

77 Citations (Scopus)

Abstract

Liver disease due to hepatitis C (HCV) is an increasingly frequent indication for orthotopic liver transplantation (OLT). The aim of the current study was to analyze the causes of graft loss following OLT for chronic hepatitis C and the longterm outcome following retransplantation in a large university program. Between January 1990 and December 1995, 1183 patients underwent primary OLT at our center. In 304 patients, HCV was diagnosed by seropositivity and/or polymerase chain reaction. Fifty-six (18.4%) of these patients underwent retransplantation. The 36 patients retransplanted for primary non-function were excluded from further analysis. The other indications for regrafting (>30 days following primary transplant) included hepatic artery thrombosis (5), chronic rejection (4), severe HCV recurrence (5), and other etiologies (6). The cumulative survival rates for the 248 patients who received 1 OLT (group 1) were 84% after one year and 75% after three years. The corresponding rates for the 20 non-PNF patients who were retransplanted (group 2) were 60% and 43%, respectively (P<.0001). Moreover, logistic regression analysis confirmed that patients in group 2 were more than 4 times likely to die than patients in group 1 (P<.0034; risk ratio, 4.2; 95% confidence interval 1.61 to 11.37). Patients undergoing retransplantation had a high incidence of serious infectious complications leading to mortality. Two additional patients with severe recurrent HCV died awaiting liver retransplantation. Eight of the 304 total patients (2.6%) transplanted for chronic HCV developed graft failure secondary to HCV recurrence and 6 of the 8 were retransplanted; 3 of the 6 patients retransplanted are alive without evidence of histologic recurrence (mean follow-up less than 1 year). In summary, despite the high frequency of recurrent histologic evidence of HCV following primary OLT (70% at 3 years), graft loss attributable solely to HCV is an infrequent finding. Retransplantation per se is a risk factor for a fatal outcome, and the indication for reOLT does not appear to impact ultimate outcome. Serious infectious complications were the leading cause of mortality in patients retransplanted. Furthermore, given the indolent natural history of HCV, longer follow-up is necessary to determine the ultimate rate of graft loss due to HCV recurrence.

Original languageEnglish
Pages (from-to)1773-1776
Number of pages4
JournalTransplantation
Volume62
Issue number12
DOIs
StatePublished - Dec 27 1996
Externally publishedYes

Fingerprint

Chronic Hepatitis C
Liver Transplantation
Transplants
Recurrence
Fatal Outcome
Mortality
Hepatic Artery
Hepatitis C
Natural History
Liver Diseases
Thrombosis
Survival Rate
Logistic Models
Odds Ratio
Regression Analysis
Confidence Intervals

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Rosen, H. R., O'Reilly, P. M., Shackleton, C. R., Mcdiarmid, S., Holt, C., Busuttil, R. W., & Martin, P. (1996). Graft loss following liver transplantation in patients with chronic hepatitis C. Transplantation, 62(12), 1773-1776. https://doi.org/10.1097/00007890-199612270-00015

Graft loss following liver transplantation in patients with chronic hepatitis C. / Rosen, Hugo R.; O'Reilly, Patrick M.; Shackleton, Christopher R.; Mcdiarmid, Sue; Holt, Curtis; Busuttil, Ronald W.; Martin, Paul.

In: Transplantation, Vol. 62, No. 12, 27.12.1996, p. 1773-1776.

Research output: Contribution to journalArticle

Rosen, HR, O'Reilly, PM, Shackleton, CR, Mcdiarmid, S, Holt, C, Busuttil, RW & Martin, P 1996, 'Graft loss following liver transplantation in patients with chronic hepatitis C', Transplantation, vol. 62, no. 12, pp. 1773-1776. https://doi.org/10.1097/00007890-199612270-00015
Rosen HR, O'Reilly PM, Shackleton CR, Mcdiarmid S, Holt C, Busuttil RW et al. Graft loss following liver transplantation in patients with chronic hepatitis C. Transplantation. 1996 Dec 27;62(12):1773-1776. https://doi.org/10.1097/00007890-199612270-00015
Rosen, Hugo R. ; O'Reilly, Patrick M. ; Shackleton, Christopher R. ; Mcdiarmid, Sue ; Holt, Curtis ; Busuttil, Ronald W. ; Martin, Paul. / Graft loss following liver transplantation in patients with chronic hepatitis C. In: Transplantation. 1996 ; Vol. 62, No. 12. pp. 1773-1776.
@article{bdda167658bc4d8a9d8047653a5a945b,
title = "Graft loss following liver transplantation in patients with chronic hepatitis C",
abstract = "Liver disease due to hepatitis C (HCV) is an increasingly frequent indication for orthotopic liver transplantation (OLT). The aim of the current study was to analyze the causes of graft loss following OLT for chronic hepatitis C and the longterm outcome following retransplantation in a large university program. Between January 1990 and December 1995, 1183 patients underwent primary OLT at our center. In 304 patients, HCV was diagnosed by seropositivity and/or polymerase chain reaction. Fifty-six (18.4{\%}) of these patients underwent retransplantation. The 36 patients retransplanted for primary non-function were excluded from further analysis. The other indications for regrafting (>30 days following primary transplant) included hepatic artery thrombosis (5), chronic rejection (4), severe HCV recurrence (5), and other etiologies (6). The cumulative survival rates for the 248 patients who received 1 OLT (group 1) were 84{\%} after one year and 75{\%} after three years. The corresponding rates for the 20 non-PNF patients who were retransplanted (group 2) were 60{\%} and 43{\%}, respectively (P<.0001). Moreover, logistic regression analysis confirmed that patients in group 2 were more than 4 times likely to die than patients in group 1 (P<.0034; risk ratio, 4.2; 95{\%} confidence interval 1.61 to 11.37). Patients undergoing retransplantation had a high incidence of serious infectious complications leading to mortality. Two additional patients with severe recurrent HCV died awaiting liver retransplantation. Eight of the 304 total patients (2.6{\%}) transplanted for chronic HCV developed graft failure secondary to HCV recurrence and 6 of the 8 were retransplanted; 3 of the 6 patients retransplanted are alive without evidence of histologic recurrence (mean follow-up less than 1 year). In summary, despite the high frequency of recurrent histologic evidence of HCV following primary OLT (70{\%} at 3 years), graft loss attributable solely to HCV is an infrequent finding. Retransplantation per se is a risk factor for a fatal outcome, and the indication for reOLT does not appear to impact ultimate outcome. Serious infectious complications were the leading cause of mortality in patients retransplanted. Furthermore, given the indolent natural history of HCV, longer follow-up is necessary to determine the ultimate rate of graft loss due to HCV recurrence.",
author = "Rosen, {Hugo R.} and O'Reilly, {Patrick M.} and Shackleton, {Christopher R.} and Sue Mcdiarmid and Curtis Holt and Busuttil, {Ronald W.} and Paul Martin",
year = "1996",
month = "12",
day = "27",
doi = "10.1097/00007890-199612270-00015",
language = "English",
volume = "62",
pages = "1773--1776",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

TY - JOUR

T1 - Graft loss following liver transplantation in patients with chronic hepatitis C

AU - Rosen, Hugo R.

AU - O'Reilly, Patrick M.

AU - Shackleton, Christopher R.

AU - Mcdiarmid, Sue

AU - Holt, Curtis

AU - Busuttil, Ronald W.

AU - Martin, Paul

PY - 1996/12/27

Y1 - 1996/12/27

N2 - Liver disease due to hepatitis C (HCV) is an increasingly frequent indication for orthotopic liver transplantation (OLT). The aim of the current study was to analyze the causes of graft loss following OLT for chronic hepatitis C and the longterm outcome following retransplantation in a large university program. Between January 1990 and December 1995, 1183 patients underwent primary OLT at our center. In 304 patients, HCV was diagnosed by seropositivity and/or polymerase chain reaction. Fifty-six (18.4%) of these patients underwent retransplantation. The 36 patients retransplanted for primary non-function were excluded from further analysis. The other indications for regrafting (>30 days following primary transplant) included hepatic artery thrombosis (5), chronic rejection (4), severe HCV recurrence (5), and other etiologies (6). The cumulative survival rates for the 248 patients who received 1 OLT (group 1) were 84% after one year and 75% after three years. The corresponding rates for the 20 non-PNF patients who were retransplanted (group 2) were 60% and 43%, respectively (P<.0001). Moreover, logistic regression analysis confirmed that patients in group 2 were more than 4 times likely to die than patients in group 1 (P<.0034; risk ratio, 4.2; 95% confidence interval 1.61 to 11.37). Patients undergoing retransplantation had a high incidence of serious infectious complications leading to mortality. Two additional patients with severe recurrent HCV died awaiting liver retransplantation. Eight of the 304 total patients (2.6%) transplanted for chronic HCV developed graft failure secondary to HCV recurrence and 6 of the 8 were retransplanted; 3 of the 6 patients retransplanted are alive without evidence of histologic recurrence (mean follow-up less than 1 year). In summary, despite the high frequency of recurrent histologic evidence of HCV following primary OLT (70% at 3 years), graft loss attributable solely to HCV is an infrequent finding. Retransplantation per se is a risk factor for a fatal outcome, and the indication for reOLT does not appear to impact ultimate outcome. Serious infectious complications were the leading cause of mortality in patients retransplanted. Furthermore, given the indolent natural history of HCV, longer follow-up is necessary to determine the ultimate rate of graft loss due to HCV recurrence.

AB - Liver disease due to hepatitis C (HCV) is an increasingly frequent indication for orthotopic liver transplantation (OLT). The aim of the current study was to analyze the causes of graft loss following OLT for chronic hepatitis C and the longterm outcome following retransplantation in a large university program. Between January 1990 and December 1995, 1183 patients underwent primary OLT at our center. In 304 patients, HCV was diagnosed by seropositivity and/or polymerase chain reaction. Fifty-six (18.4%) of these patients underwent retransplantation. The 36 patients retransplanted for primary non-function were excluded from further analysis. The other indications for regrafting (>30 days following primary transplant) included hepatic artery thrombosis (5), chronic rejection (4), severe HCV recurrence (5), and other etiologies (6). The cumulative survival rates for the 248 patients who received 1 OLT (group 1) were 84% after one year and 75% after three years. The corresponding rates for the 20 non-PNF patients who were retransplanted (group 2) were 60% and 43%, respectively (P<.0001). Moreover, logistic regression analysis confirmed that patients in group 2 were more than 4 times likely to die than patients in group 1 (P<.0034; risk ratio, 4.2; 95% confidence interval 1.61 to 11.37). Patients undergoing retransplantation had a high incidence of serious infectious complications leading to mortality. Two additional patients with severe recurrent HCV died awaiting liver retransplantation. Eight of the 304 total patients (2.6%) transplanted for chronic HCV developed graft failure secondary to HCV recurrence and 6 of the 8 were retransplanted; 3 of the 6 patients retransplanted are alive without evidence of histologic recurrence (mean follow-up less than 1 year). In summary, despite the high frequency of recurrent histologic evidence of HCV following primary OLT (70% at 3 years), graft loss attributable solely to HCV is an infrequent finding. Retransplantation per se is a risk factor for a fatal outcome, and the indication for reOLT does not appear to impact ultimate outcome. Serious infectious complications were the leading cause of mortality in patients retransplanted. Furthermore, given the indolent natural history of HCV, longer follow-up is necessary to determine the ultimate rate of graft loss due to HCV recurrence.

UR - http://www.scopus.com/inward/record.url?scp=0030443920&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030443920&partnerID=8YFLogxK

U2 - 10.1097/00007890-199612270-00015

DO - 10.1097/00007890-199612270-00015

M3 - Article

C2 - 8990361

AN - SCOPUS:0030443920

VL - 62

SP - 1773

EP - 1776

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 12

ER -